亚洲乱码一区二区三区在线观看-久青草影院在线观看国产-99精品国产福久久久久久-中文字幕亚洲一区二区va在线-欧美亚洲日韩在线在线影院

A leader in early detection, diagnosis, and intervention of chronic diseases 

Safeguarding Your Well-being from Chronic Diseases

About BioChain

A leader in early detection, diagnosis, and intervention of chronic diseases

Founded in 2006, BioChain (Beijing) Science & Technology, Inc., or BioChain for short, has since become an industry leader in the early detection, diagnosis, and intervention (hereinafter referred to as the “Triple E”) of chronic diseases. The Company diligently works in the prevention of cancer, cardiovascular and cerebrovascular diseases, diabetes, cognitive disorders, and other chronic diseases. BioChain is committed to providing targeted and safe Triple E products and services with higher medication adherence and broader applicability in the early phase of diseases.

BioChain’s blood-based DNA methylation assay kits for both colorectal cancer (CRC) and gastric cancer are the first self-developed DNA methylation diagnostic products approved by the National Medical Products Administration (NMPA) in China. In addition, they have been applied in hundreds of top-tier hospitals and incorporated into the medical insurance system in many parts of the country. The Company has an impressive pipeline of proprietary products, including the point-of-care monitoring (POCM) series, early diagnostic tools for esophageal, liver, and lung cancers, respectively. It also has a multi-cancer NGS screening platform. Furthermore, BioChain is committed to developing initiatives to diagnose and treat stroke and other cardiovascular and cerebrovascular diseases at an early stage. With the goal of “Safeguarding Your Well-being from Chronic Diseases,” BioChain will continue to refine and expand its “Triple E” applications.

 View More  

Technological Innovations

The leading innovator in the “Triple E*” approach to chronic diseases

The World’s First

The world’s first blood-based DNA methylation assay kit for the early diagnosis of CRC to be approved by the authoritative FDA (U.S.), NMPA (China), and CE marking (Europe), filling the gap at home and abroad.

The World’s Only

The world’s only DNA methylation assay kit for the early diagnosis of gastric cancer, approved by the NMPA in China.

China’s First

The first NMPA-approved DNA methylation assay kit for the early diagnosis of colorectal cancer in China.

China’s First

The first DNA methylation assay kits for early diagnosis of CRC and gastric cancer in China which have been incorporated into the medical insurance system.

China’s Only

The only company in China to receive two NMPA approvals for innovative medical devices in the field of early cancer diagnosis based on DNA methylation.

Successively selected

Consistently chosen for the China National Key R&D Program during the 13th and 14th Five-Year Plan periods.

World’s Largest

Partnered with Beijing Tiantan Hospital to establish the first Epigenetics Research Joint Laboratory in China. It also participated in the world’s largest cohort study of cerebrovascular accidents (or strokes) in epigenetic studies, involving more than 10,000 participants.

Product System

Comprehensive solutions for the “Triple E*” approach to chronic diseases.

Cancer

 View More  

Other Chronic Diseases

 View More  

Infectious Diseases

 View More  

Others

 View More  

Authoritative Certifications

Dedicated to developing excellent products and services for the “Triple E*” approach to chronic diseases

At BioChain, we always prioritize the needs of the customer. We have established a comprehensive system for product registration, production management, and quality control that is highly efficient, pragmatic, and fully regulatory-compliant. Every aspect of our operations, from R&D to registration, procurement, production, sales, logistics, and clinical testing services, adheres strictly to quality regulations and standard operating procedures. This approach provides a solid foundation for the development of exceptional products and services that meet the highest standards of excellence.

Product Registration Certificate

NMPA (the National Medical Products Administration, China) Approval

• Dozens of proprietary products have obtained NMPA approval
• Both DNA methylation test kits for the early diagnosis of colorectal cancer (思博定®) and gastric cancer (思博衛(wèi)®) were the first self-developed diagnostic products approved by the NMPA for innovative Class III medical devices

CE Approval

• By 2023, BioChain has received CE marking for a total of 49 proprietary products, including the early cancer detection and diagnostic series, the Point-of-Care Monitoring (POCM) series, and the Novel Coronavirus antibody detection series

Quality Control Certifications 

ISO (International Organization for Standardization) Certification

• Acquired ISO13485 certification, the international standard for quality assurance of medical devices

NCCL (National Center for Clinical Laboratories, China) Certification

• From 2015 to 2022, BioChain’s wholly-owned Medical Laboratory acquired the NCCL external quality assessment (EQA) certificate with full scores for 8 consecutive years

主站蜘蛛池模板: 国产高清乱码又大又圆| 精品一区二区三区免费播放| 亚洲国产成人精品无码区一本| 亚洲aⅴ综合色区无码一区| 亚洲欧美成人久久综合中文网| 奇米777四色影视在线看| 在线看片免费人成视频久网下载| 伊人亚洲综合网色| 亚洲乱亚洲乱少妇无码99p| 成人小说亚洲一区二区三区| 色噜噜一区二区三区| 国产精品久久香蕉免费播放| 超清制服丝袜无码av福利网| 国产在线高清理伦片a| 久久日本片精品aaaaa国产| 亚洲国产精品久久久久久久| 日本少妇被黑人猛cao| 人妻免费久久久久久久了| 亚洲毛片不卡av在线播放一区| 日韩欧美猛交xxxxx无码| 激情综合色综合啪啪五月丁香| 无码中文精品视视在线观看| 男人扒开女人内裤强吻桶进去| 精品人妻无码一区二区三区换脸| 羞羞色男人的天堂| 国产成人拍精品视频午夜网站 | 五月天中文字幕mv在线| 欧洲女人牲交性开放视频| а天堂8中文最新版在线官网| 美女裸体视频永久免费| 永久免费的无码中文字幕| 97超级碰碰碰久久久久| 亚洲精品色播一区二区| 中国凸偷窥xxxx自由视频妇科| 欧美日韩在线亚洲二区综二| 久久综合九色综合欧美就去吻| 久久久久久久无码高潮| 丰满人妻熟妇乱又伦精品视频三 | 偷拍激情视频一区二区三区| 高清国产亚洲精品自在久久| 欧美亚洲综合成人a∨在线|